JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
By C. Harrison, J. Kiladjian, H. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. Mcquitty, D. Hunter, R. Levy, L. Knoops and 4 more. New England Journal of Medicine, 2012
1,729 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Physiology
View Paper: https://www.semanticscholar.org/paper/1d398fe87edb16116144f2bf15ddc7fe6e4d5386
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. (2017, background): “htm, last accessed July 6, 2016).(95,96) Recent studies have shown in vivo efficacy of ruxolitinib in JAK-activated Philadelphia chromosomeelike acute lymphoblastic leukemia.”